Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGMDMXF 67 3-Year EBITDA Growth Rate is 2.20% as of Jun. 2026, which is 38% above its 10-year median of 1.60. GuruFocus rates MDMXF with a GF Score™ of 67/100 and a GF Value™ of $17.10. The stock has 6 warning signs investors should review. Among 2,595 Industrial Products companies, Medmix AG ranks worse than 53.6% on this metric.
During the past 12 months, Medmix AG's average EBITDA Per Share Growth Rate was -1.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medmix AG was 5.30% per year. The lowest was -15.60% per year. And the median was 1.60% per year.
Medmix AG (OTCPK:MDMXF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medmix AG 3-Year EBITDA Growth Rate Related Terms
MDMXF vs GEV, ETN, PH: 3-Year EBITDA Growth Rate Comparison
For the Specialty Industrial Machinery subindustry, Medmix AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG 3-Year EBITDA Growth Rate vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medmix AG's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.20% mean?
Medmix AG (MDMXF) has a 3-Year EBITDA Growth Rate of 2.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medmix AG and its competitors. This is 38% above median its historical median of 1.60. According to the industry distribution chart, Medmix AG ranks #1391 out of 2595 companies in the Industrial Products industry, placing it in the top 53.6%.
Is Medmix AG's 3-Year EBITDA Growth Rate too high?
Medmix AG's current 3-Year EBITDA Growth Rate of 2.20% is 38% above median its 10-year median of 1.60. The Industrial Products industry median 3-Year EBITDA Growth Rate is 4.40. Medmix AG's value of 2.20% is 50% below this industry median. Based on the distribution chart, Medmix AG ranks #1391 out of 2595 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Medmix AG has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's 3-Year EBITDA Growth Rate compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #1391 out of 2595 companies for 3-Year EBITDA Growth Rate. This places Medmix AG in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 4.40. Medmix AG's value of 2.20% is 50% below this benchmark. While the company's 10-year median is 1.60 vs. the industry median of 4.40, Medmix AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for an Industrial Products company?
The median 3-Year EBITDA Growth Rate among Industrial Products companies is 4.40, based on 2,595 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current 3-Year EBITDA Growth Rate of 2.20% is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medmix AG and its competitors. For the Industrial Products industry, the median 3-Year EBITDA Growth Rate is 4.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current 3-Year EBITDA Growth Rate is 2.20%, which is 38% above median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current 3-Year EBITDA Growth Rate of 2.20%. The stock's GF Value™ is $17.10, compared to a current price of $17.40 — trading 1.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.20%, which is 38% above median its 10-year median of 1.60 and 50% below the Industrial Products industry median of 4.40. Medmix AG's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medmix AG (MDMXF), the current 3-Year EBITDA Growth Rate is 2.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be overvalued.
The current stock price of $17.40 is trading 1.8% above its estimated GF Value™ of $17.10.
Key valuation signals for MDMXF:
3-Year EBITDA Growth Rate: 2.20% (38% above median its 10-year median of 1.60)
GF Value™: $17.10 vs. price of $17.40 (1.8% above fair value)
Industry Position: 50% below the Industrial Products median (#1391 of 2595)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
67GF Score
Get the complete analysis for MDMXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
